A Texas judge has finalized a $158 million settlement between Texas and a subsidiary of health care giant Johnson & Johnson in a Medicaid fraud lawsuit over the anti-psychotic drug Risperdal.
The agreement, reached during a January trial settled a lawsuit that accused J&J and its subsidiaries of fraud by false or misleading statements about the safety, cost and effectiveness of the drug.
The settlement was approved during a court hearing Tuesday in Austin.
The whistleblower lawsuit was filed by Allen Jones. His attorney, Tom Melsheimer, said Texas will get 40 percent of the settlement; the federal government gets 31 percent; Jones gets 17 percent; and 12 percent goes to attorneys’ fees.
The health care giant has said it’s not admitting fault with the settlement.
Topics Lawsuits Texas Legislation
Was this article valuable?
Here are more articles you may enjoy.
Bring It On: AI Strategy Sways Underwriter Choices of Employers 
A Chinese Spyware Tool Operates in 13 Countries, Cybersecurity Firm Says 
Allstate Introduces Large Language Model, ALLIE 
Allstate Q2 Net Income Jumps 56% on Underwriting 
